Insider Selling: G1 Therapeutics Inc (GTHX) VP Sells 750 Shares of Stock
G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.99, for a total value of $17,242.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
G1 Therapeutics Inc (NASDAQ GTHX) traded down $0.02 during trading hours on Thursday, reaching $21.51. The company had a trading volume of 2,099 shares, compared to its average volume of 73,331. G1 Therapeutics Inc has a one year low of $12.04 and a one year high of $28.67.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. equities analysts forecast that G1 Therapeutics Inc will post -2.72 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. American International Group Inc. bought a new position in G1 Therapeutics in the 3rd quarter valued at $130,000. Swiss National Bank bought a new position in G1 Therapeutics in the 4th quarter valued at $286,000. Hodges Capital Management Inc. bought a new position in G1 Therapeutics in the 4th quarter valued at $292,000. California State Teachers Retirement System bought a new position in G1 Therapeutics in the 3rd quarter valued at $319,000. Finally, Schwab Charles Investment Management Inc. bought a new position in G1 Therapeutics in the 3rd quarter valued at $364,000. 43.25% of the stock is currently owned by institutional investors.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.